1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends

Global Market Study on Diabetic Nephropathy: Asia to Witness Highest Growth by 2020

  • January 2015
  • 106 pages
  • Persistence Market Research
Report ID: 3175814

Summary

Table of Contents

Diabetes is a disease characterized by high blood sugar level which is caused by improper functioning of the pancreas, the organ secreting insulin in the body. Diabetic nephropathy is a disease of the kidney glomerulus and happens to be one of the most significant complications in terms of mortality and morbidity for patients with diabetes. The disease is mainly characterized by macroalbuminuria, where in a single day presence of albumin in the urine increases over 300 milligrams. In addition, diabetic nephropathy is also caused by proteinuria, imbalanced glomerular filtration rate, and hypertension. The imbalanced glomerular filtration rate of the kidney builds up waste products in the blood and increases the level of protein in the urine. Signs and symptoms of diabetic nephropathy are unknown in early stage of the disease. However, major signs and symptoms of diabetic nephropathy in its later stages are increased albumin secretion in urine, high blood pressure, ankle and leg swelling, high level of blood urea nitrogen (BUN) and serum creatinine, itching, morning weakness, nausea, vomiting, and anemia. Disease modifying therapies (DMT) that employ angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are used in the treatment of diabetic nephropathy. ACE inhibitors, such as enalapril, captopril, ramipril, and lisinopril, lower the amount of protein in the urine. ARBs and ACE inhibitors together provide greater protection to the kidney than they individually can. Major ARBs are candesartan, losartan and irbesartan.

Growing prevalence of diabetes and obesity, increasing R&D investments in drug discovery and development, and rising awareness about diabetes and kidney-related disorders are some of the major drivers of the diabetic nephropathy market. On the other hand, stringent regulatory requirements and longer approval time for drugs as well as a lack of comprehensive therapeutic management for diabetic nephropathy are major concerns for the market. Increasing usage of combination therapy is gaining popularity in diabetic nephropathy market is the recent market trends that have been observed in diabetic nephropathy market.

North America has the largest market for diabetic nephropathy, followed by Europe. Some of the fastest growing markets for diabetic nephropathy are China and Japan. This is due to increase in the diabetic population and rise in incidence rates of various kidney diseases in these countries.

This report provides in-depth analysis and estimation of the diabetic nephropathy market for the period 2014 to 2020, considering 2013 as the base year for calculation. In addition, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report. The diabetic nephropathy market is categorized on the basis of mode of treatment and geography. Based on a mode of treatment for diabetic nephropathy, the market comprises DMT. DMT is further categorised into ACE inhibitors, ARBs, diuretics, calcium channel blockers (CCBs), renin inhibitors, connective tissue growth factor (CTGF) inhibitors, antioxidant inflammation modulators (AIMs), monocyte chemoattractant protein (MCP) inhibitors, endothelin-A receptor (ETAR) antagonist, G protein-coupled receptors (GPCRs), and others. On the basis of geography, the report identifies and analyses the market size and predictions for North America, Europe, Asia, and Rest of the World (RoW).

Some of the major players in the diabetic nephropathy market are Novartis AG, Merck & Co., Inc., Pfizer, Inc., Abbott Laboratories, Sanofi, Eli Lilly and Company, Reata Pharmaceuticals, Inc., Bayer AG, AbbVie, Inc., and Mitsubishi Tanabe Pharma Corporation. These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, and financial overview.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Market Study on Diabetic Foot Ulcer Therapeutics: Neuro-Ischemic Ulcers Segment to Dominate the Global Market in Revenue Terms Through 2024

  • $ 4900
  • Industry report
  • March 2017
  • by Persistence Market Research

In a new publication titled “Diabetic Foot Ulcer Therapeutics Market: Global Industry Analysis and Forecast, 2016–2024,” the analysts at Persistence Market Research have targeted five key geographies ...

Diabetic Retinopathy Market - Global Opportunity Analysis and Industry Forecast, 2014-2022

  • $ 3840
  • Industry report
  • April 2017
  • by Allied Market Research

Diabetic retinopathy (DR) is a medical condition of the eye, which is prevalent in a diabetic individual. It is mainly caused due to damage of the blood vessels of the light-sensitive tissue present at ...

Diabetic Retinopathy - Epidemiology Forecast To 2023

  • $ 2750
  • Industry report
  • May 2017
  • by Delve Insight

DelveInsight’s Diabetic Retinopathy - Epidemiology Forecast to 2023 Report provides an overview of the epidemiology trends of Diabetic Retinopathy in seven major markets (US, France, Germany, Italy, ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.